Ceftolozane / Tazobactam Dosage

Medically reviewed by Drugs.com. Last updated on Jun 19, 2023.

Usual Adult Dose for Intraabdominal Infection

1.5 g IV every 8 hours
Duration of therapy: 4 to 14 days

Comments:

• Metronidazole (500 mg IV every 8 hours) should be administered concomitantly.

Use: In combination with metronidazole, for the treatment of complicated intraabdominal infections due to susceptible Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, K pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, S constellatus, S salivarius

Usual Adult Dose for Pyelonephritis

1.5 g IV every 8 hours
Duration of therapy: 7 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Usual Adult Dose for Urinary Tract Infection

1.5 g IV every 8 hours
Duration of therapy: 7 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Usual Adult Dose for Nosocomial Pneumonia

3 g IV every 8 hours
Duration of therapy: 8 to 14 days

Uses: For the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) due to susceptible E cloacae, E coli, Haemophilus influenzae, K oxytoca, K pneumoniae, P mirabilis, P aeruginosa, Serratia marcescens

Usual Pediatric Dose for Intraabdominal Infection

Birth to less than 18 years: 30 mg/kg IV every 8 hours
Maximum dose: 1.5 g/dose
Duration of therapy: 5 to 14 days

Comments:

• Metronidazole should be administered concomitantly.

Use: In combination with metronidazole, for the treatment of complicated intraabdominal infections due to susceptible E cloacae, E coli, K oxytoca, K pneumoniae, P mirabilis, P aeruginosa, B fragilis, S anginosus, S constellatus, S salivarius

Usual Pediatric Dose for Pyelonephritis

Birth to less than 18 years: 30 mg/kg IV every 8 hours
Maximum dose: 1.5 g/dose
Duration of therapy: 7 to 14 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Usual Pediatric Dose for Urinary Tract Infection

Birth to less than 18 years: 30 mg/kg IV every 8 hours
Maximum dose: 1.5 g/dose
Duration of therapy: 7 to 14 days

Use: For the treatment of complicated urinary tract infections (including pyelonephritis) due to susceptible E coli, K pneumoniae, P mirabilis, P aeruginosa

Renal Dose Adjustments

Adult Patients:

• Complicated intraabdominal infections and complicated urinary tract infections (including pyelonephritis):
• Estimated CrCl 30 to 50 mL/min: 750 mg IV every 8 hours
• Estimated CrCl 15 to 29 mL/min: 375 mg IV every 8 hours
• HABP/VABP:
• Estimated CrCl 30 to 50 mL/min: 1.5 g IV every 8 hours
• Estimated CrCl 15 to 29 mL/min: 750 mg IV every 8 hours

Pediatric Patients (birth to less than 18 years):

• Estimated GFR 50 mL/min/1.73 m2 or less: Not recommended.

Comments:

• CrCl estimated using the Cockcroft-Gault formula; estimated GFR using an age-appropriate equation for use in the pediatric population
• CrCl should be monitored at least daily in patients with changing renal function and dose should be adjusted accordingly.
• Dose adjustment has not been established in pediatric patients with estimated GFR 50 mL/min/1.73 m2 or less.

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS:
Known serious hypersensitivity to either active component, piperacillin-tazobactam, or other members of the beta-lactam class

Safety and efficacy have not been established in patients younger than 18 years with HABP/VABP.

Consult WARNINGS section for additional precautions.

Dialysis

Adult Patients:

• Complicated intraabdominal infections and complicated urinary tract infections (including pyelonephritis):
• ESRD on hemodialysis: 750 mg IV as a single loading dose followed by 150 mg IV every 8 hours for remainder of treatment period
• HABP/VABP:
• ESRD on hemodialysis: 2.25 g IV as a single loading dose followed by 450 mg IV every 8 hours for remainder of treatment period

Comments:

• On hemodialysis days, dose should be administered at the earliest possible time after completion of dialysis.

Other Comments

3 g ceftolozane-tazobactam contains 2 g ceftolozane and 1 g tazobactam
2.25 g ceftolozane-tazobactam contains 1.5 g ceftolozane and 0.75 g tazobactam
1.5 g ceftolozane-tazobactam contains 1 g ceftolozane and 0.5 g tazobactam
750 mg ceftolozane-tazobactam contains 500 mg ceftolozane and 250 mg tazobactam
450 mg ceftolozane-tazobactam contains 300 mg ceftolozane and 150 mg tazobactam
375 mg ceftolozane-tazobactam contains 250 mg ceftolozane and 125 mg tazobactam
150 mg ceftolozane-tazobactam contains 100 mg ceftolozane and 50 mg tazobactam

Administration advice:

• Administer all doses by IV infusion over 1 hour.
• Duration of therapy should be guided by severity and site of infection and the clinical and bacteriological progress of the patient.

Storage requirements:

• Prior to reconstitution: Store refrigerated at 2C to 8C (36F to 46F); protect from light.
• After reconstitution with appropriate diluent: May hold the reconstituted solution for 1 hour before transfer and dilution in appropriate infusion bag; do not freeze.
• After dilution of reconstituted solutions with appropriate diluents: Prepared infusion bags are stable for 24 hours when stored at room temperature or 7 days when stored refrigerated at 2C to 8C (36F to 46F); do not freeze.

Reconstitution/preparation techniques:

• Must be reconstituted and then diluted; the manufacturer product information should be consulted.

IV compatibility:

• Compatible diluents for reconstitution: Sterile water for injection; 0.9% Sodium Chloride for Injection, USP
• Compatible diluents for dilution: 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP
• Compatibility with other agents has not been established; this drug should not be mixed with other agents or physically added to solutions containing other agents.

General:

• The dose is expressed as the total of ceftolozane content plus tazobactam content.
• To reduce the development of drug-resistant organisms and maintain effective therapy, antibiotics should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria.
• Culture and susceptibility information should be considered when selecting/modifying antibacterial therapy or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy.

Monitoring:

• Renal: CrCl in patients with changing renal function (at least daily); renal function in elderly patients

Patient advice:

• Avoid missing doses and complete the entire course of therapy.
• Consult healthcare provider if severe watery or bloody diarrhea develops.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer